Onkologie. 2021:15(5):213-217 | DOI: 10.36290/xon.2021.041

Surgical treatment of brain gliomas

Pavel Fadrus1, Martin Smrčka1, Vilém Juráň1, Eduard Neuman1, Marek Sova1, Miloš Duba1, Soňa Kryštofová1, Radek Lakomý2, Tomáš Kazda3, Marek Večeřa4, Tereza Kopřivová5, Václav Vybíhal1
1 Neurochirurgická klinika, Fakultní nemocnice Brno a Lékařská fakulta Masarykovy univerzity, Brno
2 Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
3 Klinika radiační onkologie, Masarykův onkologický ústav, Brno
4 CEITEC - Středoevropský technologický institut, Masarykova univerzita, Brno
5 Klinika radiologie a nukleární medicíny, Fakultní nemocnice Brno a Lékařská fakulta Masarykovy univerzity, Brno

The most common primary intra-axial brain tumours are gliomas (40-50 % of all CNS tumours). Although the predominantly invasive and infiltrative nature of gliomas is responsible for the impossibility of curative resection, the primary goal of surgical procedures is to resect these tumours as much as possible. It is now widely accepted that radical surgical resection of gliomas is significantly more effective than less radical resection or biopsy and has a positive impact on OS and PFS. The aim of this review article is to provide basic and up-to-date information on the current, so-called multimodal options, for radical surgical resection of brain gliomas.

Keywords: brain gliomas, LGG, HGG, surgical resection.

Published: October 11, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fadrus P, Smrčka M, Juráň V, Neuman E, Sova M, Duba M, et al.. Surgical treatment of brain gliomas. Onkologie. 2021;15(5):213-217. doi: 10.36290/xon.2021.041.
Download citation

References

  1. Cancer Genome Atlas Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068. Go to original source... Go to PubMed...
  2. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J. Neurosurg. 2011; 115: 3-8. Go to original source... Go to PubMed...
  3. Delgado-López PD, Corrales-García EM, Martino J, Lastra-Aras E, Dueñas-Polo MT. Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies. Clin Transl Oncol. 2017; 19(8): 931-944. Go to original source... Go to PubMed...
  4. Bradac O, Steklacova A, Kramar F, Netuka D, Benes V. Brain biopsy in 10 key points - What can a neurologist expect from the neurosurgeon and the neuropathologist? Cesk Slov Neurol N 2018; 81/114: 229-234. doi:10.14735/amcsnn2018229. Go to original source...
  5. D'Amico RS, Kennedy RC, Bruce JN. Neurosurgical oncology: advances in operative technologies and adjuncts. J Neurooncol, 2014; 119: 451-463. Go to original source... Go to PubMed...
  6. Jung TY, Jung S, Kim IY, Park SJ, Kang SS, Kim SH, Lim SC. Application of neuronavigation system to brain tumor surgery with clinical experience of 420 cases. Min. Invasive Neurosurg. 2006; 49: 210-215. Go to original source... Go to PubMed...
  7. Krieg SM, Shiban E, Droese D, Gempt J, Buchmann N, Pape H, Ryang Y-M, Meyer B, Ringel F. Predictive value and safety of intraoperative neurophysiological monitoring with motor evoked potentials in glioma surgery. Neurosurgery 2012; 70: 1060-1071. Go to original source... Go to PubMed...
  8. De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol 2012; 30: 2559-2565. Go to original source... Go to PubMed...
  9. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescenceguided surgery with 5-aminolevulinic acid forresection of malignant glioma: a randomized controlled multicentre phase III trial. Lancet Oncol 2006; 7: 392-401. Go to original source... Go to PubMed...
  10. Yamada S, Muragaki Y, Maruyama T, Komori T, Okada Y. Role of neurochemical navigation with 5-aminolevulinic acid during intraoperative MRI-guided resection of intracranial malignant gliomas. Clin Neurol Neurosurg 2015; 130: 134-139. Go to original source... Go to PubMed...
  11. Acerbi F, Broggi M, Schebesch KM, Höhne J, Cavallo C, et al. Fluorescein-Guided Surgery for Resection of High-Grade Gliomas: A Multicentric Prospective Phase II Study (FLUOGLIO). Clin Cancer Res January 2018; 24(1): 52-61. Go to original source... Go to PubMed...
  12. Nimsky C, Ganslandt O, Buchfelder M, Fahlbusch R. Intraoperative visualization for resection of gliomas: the role of functional neuronavigation and intraoperative 1.5 T MRI. Neurol. Res. 2006; 28: 482-487. Go to original source... Go to PubMed...
  13. Zhang J, Chen X, Zhao Y, Wang F, Li F, Xu B. Impact of intraoperative magnetic resonance imaging and functional neuronavigation on surgical outcome in patients with gliomas involving language areas. Neurosurg Rev 2015; 38: 319-330. Go to original source... Go to PubMed...
  14. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 2011; 12: 997-1003 Go to original source... Go to PubMed...
  15. Coburger J, Wirtz CR, König RW. Impact of extent of resection and recurrent surgery on clinical outcome and overall survival in a consecutive series of 170 patients for glioblastoma in intraoperative high field magnetic resonance imaging. Journal of Neurosurgical Sciences 2015; 61(3): 233-244. Go to original source... Go to PubMed...
  16. Prada F, Mattei L, Del Bene M, et al. Intraoperative cerebral glioma characterization with contrast enhanced ultrasound. Biomed Res Int 2014: 1-9. Go to original source... Go to PubMed...
  17. Mahboob, S, McPhillips R, Qiu H, Jiang Y, Meggs C, et al.Intraoperative Ultrasound-Guided Resection of Gliomas: A Meta-Analysis and Review of the Literature. World Neurosurgery August 2016; 92: 255-263. Go to original source... Go to PubMed...
  18. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131: 803-820. Go to original source... Go to PubMed...
  19. Wessels PH, Weber WE, Raven G, et al. Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol 2003; 2: 395-403. Go to original source... Go to PubMed...
  20. Henson JW, Gaviani P, Gonzalez RG. MRI in treatment of adult gliomas. Lancet Oncol 2005; 6: 167-175. Go to original source... Go to PubMed...
  21. Reguli Š, Cvek J, Lipina R. Difuzní low grade gliomy - jak je správně diagnostikovat a efektivně léčit? Onkologie 2019; 13(3): 129-132. Go to original source...
  22. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008, 26: 1338-1345. Go to original source... Go to PubMed...
  23. Yang K, Nath S, Koziarz A, et al. Biopsy Versus Subtotal Versus Gross Total Resection in Patients with Low-Grade Glioma: A Systematic Review and Meta-Analysis. World Neurosurgery. 2018 Dec; 120: e762-e775. DOI: 10.1016/j.wneu.2018.08.163. Go to original source... Go to PubMed...
  24. Duffau H. Long-term outcomes after supratotal resection of diffuse lowgrade gliomas: a consecutive series with 11year follow-up. Acta Neurochir 2016; 158: 51-8. doi: 10.1007/s00701-015-2621-3 Go to original source... Go to PubMed...
  25. Wen PY, Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 2008; 359: 492-507. Go to original source... Go to PubMed...
  26. Lacroix M, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. 2001; 95: 190-198. Go to original source... Go to PubMed...
  27. Young RM, Jamshidi A, Davis G, Sherman JH. Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med 2015; 3(9): 121. doi: 10.3978/j.issn.2305-5839.2015.05.10 Go to original source... Go to PubMed...
  28. Tully PA, Gogos AJ, Love C, Liew D, Drummond KJ, Morokoff AP. Reoperation for recurrent glioblastoma and its association with survival benefit. Neurosurgery. 2016; 79(5): 678-89. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.